Home › Funds › Paradigm Biocapital Advisors LP › EWTX
Paradigm Biocapital Advisors LP position in EWTX
EDGEWISE THERAPEUTICS INC · Health Care
Paradigm Biocapital Advisors LP reported holding 10,778,665 shares of EWTX (EDGEWISE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$437.6M, representing 8.70% of its reported portfolio and ranking #3 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed EWTX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Paradigm Biocapital Advisors LP's EWTX position evolved
Paradigm Biocapital Advisors LP first disclosed a stake in EWTX in Q1 2024 at 2,446,373 shares (US$44.6M). The position peaked in Q3 2026 at 10,778,665 shares, worth US$437.6M. Across 11 filings, Paradigm Biocapital Advisors LP increased the stake 7 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 10,778,665 shares valued at US$437.6M — an increase of 563,210 shares quarter over quarter.. Notable position changes include a 61% increase in Q4 2024 (shares fell 18% over the following quarter), a 89% trim in Q1 2025 (shares fell 40% over the following quarter), a 1128% increase in Q2 2025 (shares rose 24% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 2.45M | $44.62M | New |
| Q2 2024 | 2.33M | $41.88M | Reduce |
| Q3 2024 | 2.79M | $74.44M | Add |
| Q4 2024 | 4.49M | $119.99M | Add |
| Q1 2025 | 500.00K | $11.00M | Reduce |
| Q2 2025 | 6.14M | $80.53M | Add |
| Q3 2025 | 6.17M | $100.08M | Hold |
| Q4 2025 | 6.54M | $162.32M | Add |
| Q1 2026 | 7.37M | $232.00M | Add |
| Q2 2026 | 10.22M | $415.05M | Add |
| Q3 2026 | 10.78M | $437.61M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EWTX and 13F data
EWTX (EDGEWISE THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in EWTX — the largest reported positions include ORBIMED ADVISORS LLC (US$630.5M), RA CAPITAL MANAGEMENT, L.P. (US$341.0M), Novo Holdings A/S (US$217.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EWTX
- ORBIMED ADVISORS LLC 15.52M sh · $630.52M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 8.39M sh · $341.00M · Q2 2026
- Novo Holdings A/S 5.35M sh · $217.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 4.40M sh · $178.72M · Q3 2026
- PERCEPTIVE ADVISORS LLC 4.37M sh · $177.71M · Q2 2026
- BAKER BROS. ADVISORS LP 3.70M sh · $150.40M · Q2 2026
- Siren, L.L.C. 2.80M sh · $113.85M · Q3 2026
- Cormorant Asset Management, LP 2.51M sh · $101.98M · Q2 2026
- BRAIDWELL LP 2.00M sh · $81.14M · Q2 2026
- MPM BioImpact LLC 1.62M sh · $65.85M · Q2 2026
- Deep Track Capital, LP 1.15M sh · $46.64M · Q3 2026
- First Light Asset Management, LLC 1.10M sh · $44.50M · Q2 2026
More on Paradigm Biocapital Advisors LP
FAQ
How long has Paradigm Biocapital Advisors LP held EWTX?
Paradigm Biocapital Advisors LP has disclosed EWTX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Paradigm Biocapital Advisors LP's current position in EWTX?
As of Q3 2026, Paradigm Biocapital Advisors LP holds 10.78M shares of EWTX (EDGEWISE THERAPEUTICS INC), valued at $437.61M, representing 8.70% of its reported portfolio and ranking #3.
Has Paradigm Biocapital Advisors LP been buying or selling EWTX?
In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP increased its position in EWTX. The position peaked in Q3 2026 at 10.78M shares.
Which other funds hold EWTX?
Other major institutional holders of EWTX include ORBIMED ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.